Trial Profile
Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Multifocal motor neuropathy
- Focus Therapeutic Use
- 16 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
- 23 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.